Beactica’s integrated fragment-based platform, Sprint™, offers a way to quickly identify optimal starting points and development routes for new drug candidates. It gives unique information about how the fragments interact with the target protein in question.
Sprint™ accelerates the identification of selective compounds with a high development potential through careful consideration of molecular properties in combination with a unique interaction analysis system. The approach reduces the risk of failure in both early and late stages of the drug discovery process.
Sprint™ works also when protein crystallisation is not possible. This enables us to work with wider range of protein targets.
